8-K Announcements
6Material company update
Jan 7, 2026·SEC
Material company update
Nov 14, 2025·SEC
Material company update
Nov 6, 2025·SEC
Cidara Therapeutics has transitioned into a pure-play, milestone-dependent research platform, effectively eliminating commercial revenue streams while aggressively scaling R&D expenditures to $35.5 million in 2025Q3. While recent capital raises have bolstered ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
The company has experienced a total revenue collapse, reporting zero revenue for multiple consecutive quarters following a 94.52% year-over-year decline as it pivots away from commercial product sales.
Investors can monitor real-time stock data, financials, and news for Cidara Therapeutics to make informed decisions.
Detailed financial and revenue forecasts for 2026 provide insights into the company's growth potential.
Availability of earnings transcripts allows investors to analyze management commentary and future guidance.
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 6, 2025 | -$3.10-131.3% vs -$1.34 | — vs — |
Q3 2025 Aug 7, 2025 | -$1.65+11.8% vs -$1.87 | — vs — |
Q2 2025 May 8, 2025 | -$1.66+69.5% vs -$5.45 | — vs — |
Q2 2025 Mar 6, 2025 | -$5.38-1.9% vs -$5.28 | — vs $240,000 |
Benchmark CDTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cidara Therapeutics, Inc. (CDTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $221.38 | $1.41B | -8.28 | -94.52% | -13319.76% | -218.99% | — | |
| $19.73 | $3.38B | 8.62 | 11.87% | 33.42% | 32.39% | — | |
| $37.00 | $2.2B | -5.20 | 48.03% | -418.24% | -35.67% | — | |
| $252.96 | $7.05B | -18.77 | -100% | — | -34.15% | — | |
| $11.64 | $338.47M | -3.03 | -3.42% | -96.89% | -61.84% | — | |
| $2.25 | $143.02M | -1.91 | 0.78% | -8.7% | -31.27% | — |
Cidara Therapeutics, Inc. (CDTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cidara Therapeutics, Inc. (CDTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jan 7, 2026·SEC
Nov 14, 2025·SEC
Nov 6, 2025·SEC
Mar 6, 2025·SEC
Get notified when CDTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cidara Therapeutics, Inc. (CDTX) stock FAQ — growth, dividends, profitability & financials explained
Cidara Therapeutics, Inc. (CDTX) reported $1.3M in revenue for fiscal year 2024.
Cidara Therapeutics, Inc. (CDTX) saw revenue decline by 94.5% over the past year.
Cidara Therapeutics, Inc. (CDTX) reported a net loss of $184.7M for fiscal year 2024.
Cidara Therapeutics, Inc. (CDTX) has a return on equity (ROE) of -219.0%. Negative ROE indicates the company is unprofitable.
Cidara Therapeutics, Inc. (CDTX) had negative free cash flow of $132.9M in fiscal year 2024, likely due to heavy capital investments.